Centre de Recherche en Transplantation et Immunologie UMR1064, INSERM, Université de Nantes, Nantes, France; Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
Département de Thérapie Cellulaire, CHU Saint Louis, Paris, France.
J Hepatol. 2017 Apr;66(4):765-777. doi: 10.1016/j.jhep.2016.11.019. Epub 2016 Nov 30.
BACKGROUND & AIMS: Induction of donor-specific immune tolerance is a good alternative to chronic life-long immunosuppression for transplant patients. Donor major histocompatibility complex (MHC) molecules represent the main targets of the allogeneic immune response of transplant recipients. Liver targeted gene transfer with viral vectors induces tolerance toward the encoded antigen. The aim of this work was to determine whether alloantigen gene transfer to hepatocytes induces tolerance and promotes graft acceptance.
C57BL/6 (H-2b) mice were treated with adeno-associated viral (AAV) vector targeting the expression of the MHC class I molecule H-2K to hepatocytes, before transplantation with fully allogeneic pancreatic islet from BALB/c mice (H-2d).
AAV H-2K treated mice were tolerant to the alloantigen, as demonstrated by its long-term expression by the hepatocytes, even after a highly immunogenic challenge with an adenoviral vector. After chemical induction of diabetes, the AAV treated mice had significantly delayed rejection of fully allogeneic pancreatic islet grafts, with more than 40% of recipients tolerant (>100days). AAV-mediated expression of H-2K in the liver induced the local expansion of CD8 T lymphocytes with allo-specific suppressive properties. The adoptive transfer of these liver-generated CD8 Tregs into naive diabetic mice promoted the long-term survival of allogeneic pancreatic islet grafts.
AAV-mediated long-term expression of a single MHC class I molecule in the liver induces the generation of a subset of allo-specific CD8 Treg cells, which promote tolerance toward fully allogeneic graft. Liver gene transfer represents a promising strategy for in vivo induction of donor-specific tolerance.
The liver has a special immune system, biased toward tolerance. In this study, we investigated the possibility of harnessing this property of the liver to induce tolerance to an allogeneic transplantation. We demonstrate for the first time that the in vivo gene transfer of an allogeneic antigen with an adeno-associated viral vector to mouse hepatocytes induces the expansion of a population of CD8 regulatory T lymphocytes. These Tregs are then instrumental in preventing the rejection of allogeneic pancreatic islets transplanted in these animals. Allogeneic transplantation is the main treatment for the end-stage diseases of a number of organs. Life-long immunosuppressive treatments are still required to limit graft rejection, and these treatments exhibit serious side effects. Our present findings open a new avenue for promoting allo-specific tolerance via in vivo induction of CD8 Treg expansion.
诱导供体特异性免疫耐受是移植患者替代慢性终身免疫抑制的一种良好选择。供体主要组织相容性复合物(MHC)分子是移植受者同种异体免疫反应的主要靶标。病毒载体的肝靶向基因转移诱导对编码抗原的耐受。本研究的目的是确定将同种抗原基因转移到肝细胞是否诱导耐受并促进移植物接受。
在接受来自 BALB/c 小鼠(H-2d)的完全同种异体胰岛移植之前,用腺相关病毒(AAV)载体靶向 MHC Ⅰ类分子 H-2K 的表达对 C57BL/6(H-2b)小鼠进行治疗。
AAV H-2K 处理的小鼠对同种抗原具有耐受性,这表现在即使在用腺病毒载体进行高度免疫原性挑战后,肝细胞仍能长期表达。在化学诱导糖尿病后,AAV 处理的小鼠的完全同种异体胰岛移植物排斥明显延迟,超过 40%的受者耐受(>100 天)。AAV 在肝脏中介导的 H-2K 表达诱导具有同种特异性抑制特性的 CD8 T 淋巴细胞的局部扩增。将这些在肝脏中产生的 CD8 Treg 细胞过继转移到未致敏的糖尿病小鼠中,可促进完全同种异体胰岛移植物的长期存活。
AAV 介导的单个 MHC Ⅰ类分子在肝脏中的长期表达诱导了一组同种特异性 CD8 Treg 细胞的产生,从而促进了对完全同种异体移植物的耐受。肝基因转移代表了体内诱导供体特异性耐受的一种很有前途的策略。
肝脏具有特殊的免疫系统,偏向于耐受。在这项研究中,我们研究了利用肝脏的这种特性来诱导对同种异体移植的耐受性的可能性。我们首次证明,用腺相关病毒载体将同种异体抗原体内基因转移到小鼠肝细胞中会诱导 CD8 调节性 T 淋巴细胞的扩增。这些 Treg 细胞随后在防止这些动物中移植的同种异体胰岛排斥中起关键作用。同种异体移植是许多器官终末期疾病的主要治疗方法。为了限制移植物排斥,仍然需要终身免疫抑制治疗,而这些治疗方法存在严重的副作用。我们目前的研究结果为通过体内诱导 CD8 Treg 扩增来促进同种特异性耐受开辟了新途径。